Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Novo Nordisk A/S — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.75, while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals.
| JNK | NVO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $98.19 | $63.98 |
52-Week Low | $94.66 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.85, up 0.21% with a bearish technical signal from moving averages and oscillators neutral. Recent news highlights bond market volatility amid inflation data and Middle East tensions, with Fitch Ratings warning of AI-related corporate credit risks. The ETF maintains dividend distributions, with recent payouts around $0.52-$0.53.
Outlook is cautious due to macroeconomic headwinds and credit risks, but higher yields may attract income investors. Key risks include Fed policy uncertainty and oil price fluctuations impacting bond markets. Analyst sentiment is mixed, balancing yield appeal against fee concerns and market volatility.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
